Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Can PCE Induction Improve Outcomes in Advanced HNSCC?
CDK4/6 in EBC After ESMO: From Early Signals to Greater Clarity
Javier Cortes, MD, PhD
From Eligibility to Treatment Planning: Translating ESMO Data Into Adjuvant CDK4/6 Decision-Making
Stephanie Graff, MD
Can MRI Predict Active Surveillance Failure in Desmoid-Type Fibromatosis?
Ryan Quigley
How Cancer Worry Influences Smoking Cessation
Hermine Poghosyan, PhD
Cryoablation Offers Local Control for Extra-Abdominal Desmoid Tumors
Making the Most of Biomarker Testing in NSCLC
Steve Jackson, PharmD
Angel Qin, MD
KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Gerard A. Silvestri MD, MS
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
The Search for Radioresistance Biomarkers in Head and Neck Squamous Cell Carcinoma
Heath Skinner, MD, PhD
Key Drivers of Radioresistance in Head and Neck Squamous Cell Carcinoma
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Alexandria May, PharmD, BCPS
Tara Graff, DO, MS
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
Redefining Recurrence Risk in HR+/HER2− Early Breast Cancer: Applying Evolving CDK4/6 Inhibitor Evidence to Adjuvant Treatment Decisions
Test Before You Treat: Biomarkers That Shape CLL Care
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Biomarker Testing After Progression in HR+/HER2- mBC
Adam Brufsky, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.